RC118G001
20 Apr 2022
SOC2105
NCT04914117
Phase 1, First-in-Human, Multicentre, Open-label Study of RC118 for Injection in Patients With Locally Advanced Unresectable/Metastatic Solid Tumours
RemeGen Co.
Cancer Type | All cancers |
---|---|
Trial Type | Treatment |
Phase | Phase I |
Age Range | 18 years to 75 years |
Sex | All |
Tumour Stream | - |
Cancer Stage | Locally Recurrent or Locally Advanced; Metastatic or Widespread |
Anticipated Start Date | 2021-11-29 |
Anticipated End Date | 2023-05-30 |
Hospital | Southern Oncology Clinical Research Unit |
---|---|
Clinical Trial Coordinator | Meggan O'Riley |
Meggan.ORiley@socru.org.au | |
Phone | 0491 679 039 |
Principal Investigator | Dr Ganessan Kichenadasse |
Recruitment Status | Recruiting |
Keep up to date with the latest news and breakthroughs